File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Better efficacy of tegaserod in constipated patients with slow colonic transit, absent pelvic floor dyssynergy and absent impaired rectal sensation

TitleBetter efficacy of tegaserod in constipated patients with slow colonic transit, absent pelvic floor dyssynergy and absent impaired rectal sensation
Authors
Issue Date2007
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
Digestive Disease Week and the 108th Annual Meeting of the American Gastroenterological Association Institute, Washington, DC, 19-24 May 2007. In Gastroenterology, 2007, v. 132 n. 4, p. A-194 Abstract no. S1198 How to Cite?
AbstractObjective: Functional constipation comprises of slow transit and pelvic floor dyssynergy. Tegaserod has been shown to be effective in patients with functional constipation. We aimed at identifying the subgroup of constipated patients who responded the best to tegaserod treatment. Design: 250 patients were randomized for tegaserod or placebo treatment. Colonic transit time and anorectal manometry were performed and available for analysis in 216 and 75 patients, respectively before the randomization period. Responders were defined as a mean increase of complete spontaneous bowel motion ≥1/week compared with the baseline. Slow colonic transit was defined as >67 hours, pelvic floor dyssynergy defined as paradoxical contraction or a failure to relax during anorectal manometry together with the feeling of outlet blockade and/or digital evacuation, impaired rectal sensation defined arbitrarily as greater than or equal to the mean balloon volume of the first sensation. Results: Demographic data were comparable in the treatment and placebo groups. The responder rate was 41% vs 20.9% (p=0.048) in slow transit, 51.4% vs 34.4% (p=0.047) in normal transit; 50% vs 30% (p=0.22) with pelvic floor dyssynergy, 54.2% vs 26.7% (p=0.087) without; 40% vs 22.2% (p=0.26) with impaired rectal sensation, 60% vs 35.3% (p=0.11) without; for the treatment and placebo groups respectively. The improvement in responder rate comparing the treatment to placebo group was best seen in those with absent pelvic floor dyssynergy, absent impaired rectal sensation, but in slow transit instead of normal transit. Conclusion: Tegaserod treatment is useful in constipated patients with slow colonic transit.
Persistent Identifierhttp://hdl.handle.net/10722/102209
ISSN
2015 Impact Factor: 18.187
2015 SCImago Journal Rankings: 7.170

 

DC FieldValueLanguage
dc.contributor.authorChan, AOOen_HK
dc.contributor.authorHui, WMen_HK
dc.contributor.authorLeung, YCen_HK
dc.contributor.authorWong, YHen_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorHung, IFHen_HK
dc.contributor.authorHsu, Aen_HK
dc.contributor.authorBut, Den_HK
dc.contributor.authorLam, SKen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2010-09-25T20:21:25Z-
dc.date.available2010-09-25T20:21:25Z-
dc.date.issued2007en_HK
dc.identifier.citationDigestive Disease Week and the 108th Annual Meeting of the American Gastroenterological Association Institute, Washington, DC, 19-24 May 2007. In Gastroenterology, 2007, v. 132 n. 4, p. A-194 Abstract no. S1198en_HK
dc.identifier.issn0016-5085en_HK
dc.identifier.urihttp://hdl.handle.net/10722/102209-
dc.description.abstractObjective: Functional constipation comprises of slow transit and pelvic floor dyssynergy. Tegaserod has been shown to be effective in patients with functional constipation. We aimed at identifying the subgroup of constipated patients who responded the best to tegaserod treatment. Design: 250 patients were randomized for tegaserod or placebo treatment. Colonic transit time and anorectal manometry were performed and available for analysis in 216 and 75 patients, respectively before the randomization period. Responders were defined as a mean increase of complete spontaneous bowel motion ≥1/week compared with the baseline. Slow colonic transit was defined as >67 hours, pelvic floor dyssynergy defined as paradoxical contraction or a failure to relax during anorectal manometry together with the feeling of outlet blockade and/or digital evacuation, impaired rectal sensation defined arbitrarily as greater than or equal to the mean balloon volume of the first sensation. Results: Demographic data were comparable in the treatment and placebo groups. The responder rate was 41% vs 20.9% (p=0.048) in slow transit, 51.4% vs 34.4% (p=0.047) in normal transit; 50% vs 30% (p=0.22) with pelvic floor dyssynergy, 54.2% vs 26.7% (p=0.087) without; 40% vs 22.2% (p=0.26) with impaired rectal sensation, 60% vs 35.3% (p=0.11) without; for the treatment and placebo groups respectively. The improvement in responder rate comparing the treatment to placebo group was best seen in those with absent pelvic floor dyssynergy, absent impaired rectal sensation, but in slow transit instead of normal transit. Conclusion: Tegaserod treatment is useful in constipated patients with slow colonic transit.-
dc.languageengen_HK
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastroen_HK
dc.relation.ispartofGastroenterologyen_HK
dc.titleBetter efficacy of tegaserod in constipated patients with slow colonic transit, absent pelvic floor dyssynergy and absent impaired rectal sensationen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0016-5085&volume=132&issue=4&spage=A194&epage=&date=2007&atitle=Better+efficacy+of+tegaserod+in+constipated+patients+with+slow+colonic+transit,+absent+pelvic+floor+dyssynergy+and+absent+impaired+rectal+sensation.++Digestive+Disease+Week+2007,+Washington+DC,+USA,+19-24+Mayen_HK
dc.identifier.emailChan, AOO: aoochan@hku.hken_HK
dc.identifier.emailHui, WM: hrmehwm@hkucc.hku.hken_HK
dc.identifier.emailLeung, YC: newgigi21@hotmail.comen_HK
dc.identifier.emailLam, SK: deanmed@hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0016-5085(07)60009-2-
dc.identifier.hkuros131418en_HK
dc.identifier.volume132en_HK
dc.identifier.issue4en_HK
dc.identifier.spage194en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats